<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320865</url>
  </required_header>
  <id_info>
    <org_study_id>Novartis AMN-107</org_study_id>
    <nct_id>NCT01320865</nct_id>
  </id_info>
  <brief_title>Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that bone marrow progenitor cells are mobilized into the
      circulation in PAH, home to the lungs and differentiate into mast cells, which promote
      vascular remodeling and vasoconstriction through release of renin and chymase. As a corollary
      to this, the investigators hypothesize that anti cKit tyrosine kinase inhibitor (TKI),
      nilotinib, provides clinical benefit to patients through inhibition of mast cell progenitor
      proliferation, mobilization and differentiation. To test this, the investigators will
      determine if mast cell progenitors and mast cell biomarkers are related to nilotinib clinical
      response. This will be an ancillary study, part of a placebo-controlled, double-blind multi
      center clinical trial of nilotinib in pulmonary arterial hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring circulating markers of Nilotinib affect</measure>
    <time_frame>within one year of the end of the study</time_frame>
    <description>We will measure markers of mast cell activation in blood and urine before and during treatment with nilotinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate effect of Nilotinib on the activation of mast cells.</measure>
    <time_frame>within one year of the end of the study</time_frame>
    <description>We will measure markers of mast cell activation in blood and urine before and during treatment with nilotinib. We will also look at the proliferation of mast cell progenitors and correlate this to clinical markers used to monitor this disease.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>PAH</condition>
  <arm_group>
    <arm_group_label>Subjects with PAH treated with nilotinib</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with PAH that are enrolled in the Nilotinib clinical trial.
        http://clinicaltrials.gov/ct2/show/NCT01179737?term=tasigna+and+pulmonary+hypertension&amp;rank
        =1
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        This study is a substudy and subjects must be enrolled in the main trial:

        See Study Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in
        Pulmonary Arterial Hypertension (PAH) In clinical trials. (clinical Trial ID NCT01179737)

        http://clinicaltrials.gov/ct2/show/NCT01179737?

        Exclusion Criteria:

        Subjects are not enrolled in the main study:

        See Study Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in
        Pulmonary Arterial Hypertension (PAH) In clinical trials. (clinical Trial ID NCT01179737)

        http://clinicaltrials.gov/ct2/show/NCT01179737?term=tasigna+and+pulmonary+hypertension&amp;rank
        =1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kewal Asosingh, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT01179737?term=tasigna+and+pulmonary+hypertension&amp;rank=1</url>
    <description>See Study: Efficacy, Safety, Tolerabilitiy and PK of AMN 107 in PAH</description>
  </link>
  <reference>
    <citation>Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med. 2006 Jul 18;145(2):152-3.</citation>
    <PMID>16847299</PMID>
  </reference>
  <reference>
    <citation>Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005 Oct;115(10):2811-21.</citation>
    <PMID>16200212</PMID>
  </reference>
  <reference>
    <citation>Dentelli P, Rosso A, Balsamo A, Colmenares Benedetto S, Zeoli A, Pegoraro M, Camussi G, Pegoraro L, Brizzi MF. C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. Blood. 2007 May 15;109(10):4264-71. Epub 2007 Feb 8.</citation>
    <PMID>17289809</PMID>
  </reference>
  <reference>
    <citation>Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol. 1991 Dec;44(12):1003-6.</citation>
    <PMID>1791199</PMID>
  </reference>
  <reference>
    <citation>Hamada H, Terai M, Kimura H, Hirano K, Oana S, Niimi H. Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am J Respir Crit Care Med. 1999 Oct;160(4):1303-8.</citation>
    <PMID>10508822</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Kewal Asosingh, Ph.D</investigator_full_name>
    <investigator_title>Associate Staff</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

